SHANGHAI ZHONGXI SUNVE PHARMACEUTICAL CO LTD

Overview

SHANGHAI ZHONGXI SUNVE PHARMACEUTICAL CO LTD is an active pharmaceutical ingredient (API) supplier with 7 active FDA Type II Drug Master Files, covering CLOZAPINE; FOSPHENYTOIN SODIUM USP; HYDROXYCHLOROQUINE SULFATE; NAFTIFINE HYDROCHLORIDE; PYRIDOSTIGMINE BROMIDE; SULFAMETHAZINE SODIUM.

API / Drug Master Files

SHANGHAI ZHONGXI SUNVE PHARMACEUTICAL CO LTD holds 7 active (14 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• PYRIDOSTIGMINE BROMIDEActive2024-04-01
• HYDROXYCHLOROQUINE SULFATEActive2023-12-27
• HYDROXYCHLOROQUINE SULFATEActive2020-07-09
• NAFTIFINE HYDROCHLORIDEActive2010-08-03
• FOSPHENYTOIN SODIUM USPActive2004-04-26
• SULFAMETHAZINE SODIUMActive1999-06-23
• CLOZAPINEActive1994-11-16
• HYDROXYCHLOROQUINE SULFATE (USP)Inactive2012-01-09
• ATENOLOLInactive2009-12-01
• SULFASALAZINEInactive2008-11-24
• CLOTRIMAZOLEInactive2006-08-29
• GEIBROZILInactive2005-02-24
• SULFADOXINEInactive2004-11-03
• SULFADIAZINEInactive1990-08-08

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to SHANGHAI ZHONGXI SUNVE PHARMACEUTICAL CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.